Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

PubWeight™: 3.85‹?› | Rank: Top 1%

🔗 View Article (PMID 17876013)

Published in J Clin Oncol on September 17, 2007

Authors

Leonard B Saltz1, Heinz-Josef Lenz, Hedy L Kindler, Howard S Hochster, Scott Wadler, Paulo M Hoff, Nancy E Kemeny, Ellen M Hollywood, Mithat Gonen, Marcus Quinones, Meroe Morse, Helen X Chen

Author Affiliations

1: Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. saltzl@MSKCC.ORG

Articles citing this

(truncated to the top 100)

Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20

Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80

Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol (2009) 2.45

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov (2010) 1.59

Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. Int J Colorectal Dis (2009) 1.50

Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol (2010) 1.47

Treatment in advanced colorectal cancer: what, when and how? Br J Cancer (2009) 1.40

Rationale for combining biotherapy in the treatment of advanced colon cancer. Gastrointest Cancer Res (2008) 1.39

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol (2010) 1.31

Finding the tumor copycat. Therapy fails, patients don't. Nat Med (2010) 1.29

Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. MAbs (2011) 1.17

More is less -- combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol (2009) 1.15

DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res (2009) 1.15

Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol (2009) 1.13

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat (2007) 1.08

Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One (2012) 1.05

Tumor angiogenesis: insights and innovations. J Oncol (2010) 1.04

Personalized colon cancer care in 2010. Semin Oncol (2011) 1.01

Safety and feasibility of targeted agent combinations in solid tumours. Nat Rev Clin Oncol (2013) 1.01

The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist (2010) 1.00

The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol (2008) 0.99

Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer (2008) 0.98

Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol (2009) 0.97

Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer (2011) 0.97

Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today (2011) 0.97

A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res (2011) 0.95

Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist (2010) 0.94

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol (2010) 0.93

Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist (2012) 0.92

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience (2014) 0.91

Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol (2012) 0.91

Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biol Ther (2011) 0.90

Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med (2012) 0.89

Antiangiogenic therapy for glioma. J Signal Transduct (2012) 0.89

Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol (2015) 0.88

Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol (2007) 0.88

A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer (2012) 0.88

Impact of KRAS Mutations on Management of Colorectal Carcinoma. Patholog Res Int (2011) 0.87

Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer (2012) 0.85

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs (2011) 0.85

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics (2008) 0.85

In pursuit of new anti-angiogenic therapies for cancer treatment. Front Biosci (Landmark Ed) (2011) 0.85

Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol (2010) 0.84

In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Gastric Cancer (2011) 0.84

Integrating anti-EGFR therapies in metastatic colorectal cancer. J Gastrointest Oncol (2013) 0.84

Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Ther Adv Med Oncol (2009) 0.84

Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol (2015) 0.83

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest New Drugs (2008) 0.83

Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs (2009) 0.83

Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. Exp Mol Pathol (2013) 0.83

Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. J Oncol (2009) 0.82

Immunotherapy for head and neck cancer: advances and deficiencies. Anticancer Drugs (2011) 0.82

Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol (2016) 0.81

Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Med (2014) 0.81

Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer. Curr Clin Pharmacol (2012) 0.81

The role of cetuximab as first-line treatment of colorectal liver metastases. HPB (Oxford) (2012) 0.81

Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases. Clin Exp Metastasis (2011) 0.81

Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Mol Med (2009) 0.81

Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet. J Clin Oncol (2007) 0.81

New advances in targeted gastric cancer treatment. World J Gastroenterol (2016) 0.81

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer (2011) 0.80

Tumor biology and cancer therapy - an evolving relationship. Cell Commun Signal (2009) 0.80

Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics (2008) 0.80

Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr Oncol (2010) 0.80

Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World J Gastroenterol (2013) 0.80

Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D (2011) 0.79

A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Invest New Drugs (2011) 0.79

Bevacizumab: one treatment for all the seasons? J Clin Oncol (2008) 0.79

Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism? J Oncol (2009) 0.79

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). Invest New Drugs (2010) 0.78

The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials. Int J Clin Exp Med (2015) 0.78

Evaluation of serum iron levels during FOLFOX4 and FOLFIRI therapies. Exp Ther Med (2010) 0.78

Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. Onco Targets Ther (2009) 0.78

Angiogenesis in head and neck cancer: a review of the literature. J Oncol (2011) 0.78

Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am (2010) 0.78

Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel) (2015) 0.78

Approaches to modernize the combination drug development paradigm. Genome Med (2016) 0.77

Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells. Int J Mol Sci (2016) 0.77

Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer. Chemother Res Pract (2012) 0.77

Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. Oncotarget (2015) 0.77

Medical treatment of advanced colorectal cancer in 2009. Ther Adv Med Oncol (2009) 0.77

Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clin Colorectal Cancer (2010) 0.77

Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. Ecancermedicalscience (2015) 0.76

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget (2016) 0.76

Evolving role of cetuximab in the treatment of colorectal cancer. Cancer Manag Res (2009) 0.76

Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics (2009) 0.76

The management of cancer in the elderly: targeted therapies in oncology. Immun Ageing (2008) 0.76

Accomplishments in 2007 in the treatment of advanced colorectal cancer. Gastrointest Cancer Res (2008) 0.76

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther (2012) 0.76

Poly-S-nitrosated human albumin enhances the antitumor and antimetastasis effect of bevacizumab, partly by inhibiting autophagy through the generation of nitric oxide. Cancer Sci (2015) 0.75

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs (2015) 0.75

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. Onco Targets Ther (2015) 0.75

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study. Transl Lung Cancer Res (2015) 0.75

A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience. Onco Targets Ther (2016) 0.75

First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. Onco Targets Ther (2009) 0.75

Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer (2016) 0.75

Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Adv Med Oncol (2010) 0.75

Adaptation to antiangiogenic therapy in neurological tumors. Cell Mol Life Sci (2015) 0.75

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care. Core Evid (2007) 0.75

Articles by these authors

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59

Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80

Colorectal cancer. Lancet (2010) 8.36

Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg (2002) 8.30

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60

Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol (2008) 4.68

Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol (2005) 3.99

Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol (2008) 3.71

Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res (2006) 3.65

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist (2007) 3.42

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39

Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell (2012) 3.39

A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34

Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32

Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20

Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20

Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16

Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg (2003) 3.14

Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med (2015) 3.09

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02

Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol (2007) 3.00

Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg (2010) 2.99

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2002) 2.89

Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg (2004) 2.86

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol (2007) 2.83

Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid (2010) 2.77

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res (2005) 2.76

Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res (2005) 2.73

Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology. J Clin Oncol (2013) 2.68

Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak (2008) 2.64

Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med (2003) 2.62

The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer (2004) 2.54

EGFR signaling and drug discovery. Oncology (2010) 2.53

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53

Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol (2007) 2.53

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol (2009) 2.52

Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol (2004) 2.51

Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol (2009) 2.50

Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med (2011) 2.49

Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg (2005) 2.38

Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol (2012) 2.38

Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg (2007) 2.37

Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg (2003) 2.36

Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31

Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab (2005) 2.30

Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol (2012) 2.29

Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol (2006) 2.29

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26

Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol (2009) 2.26

Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology (2013) 2.24

The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg (2007) 2.23

Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov (2006) 2.23

Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies. Ann Surg (2012) 2.23

Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 2.22

Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg (2007) 2.22

Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol (2004) 2.22

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood (2008) 2.20

Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer (2009) 2.18

Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: a case-control study. Ann Surg Oncol (2009) 2.10

Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2008) 2.06

Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05

Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol (2003) 2.04

Is surgery always necessary in rectal cancer? Oncology (Williston Park) (2014) 2.04

Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg (2006) 2.03

Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer (2011) 2.01

(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol (2013) 1.99

Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg (2009) 1.94

Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol (2006) 1.94

Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol (2005) 1.92

Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol (2008) 1.92

The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89

Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol (2002) 1.88

A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics (2004) 1.88

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol (2009) 1.87

Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg (2008) 1.85

Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol (2007) 1.84

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 1.83

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol (2005) 1.82

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol (2008) 1.79

Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol (2002) 1.78

Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. J Vasc Interv Radiol (2013) 1.76

Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol (2014) 1.76

Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol (2007) 1.75

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res (2008) 1.74

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73

A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res (2003) 1.73